$COLL News
Last published 6d ago
- 6d agoCOLLCOLLEGIUM PHARMACEUTICAL, INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 6d agoCOLLCollegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 GuidanceGlobeNewswire– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS® Quarterly Net
- 1w agoCOLLCollegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across MassachusettsGlobeNewswireSTOUGHTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often
- 2w agoCOLLCollegium to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswireSTOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often
- 3w agoCOLLCollegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall CongressesGlobeNewswireSTOUGHTON, Mass., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often
- 1mo agoCOLLMorgan Stanley 24th Annual Global Healthcare Conference - COLLEGIUM PHARMACEUTICAL INCEarnings Call TranscriptsGood afternoon. My name is Bob Klingenberger. I'm an executive director at Morgan Stanley. I'm really pleased to be joined by the Collegium team here this afternoon, Vikram Karnani, CEO, and Colleen Tupper, CFO. And just
- 2mo agoCOLLCollegium to Participate in Upcoming Investor ConferencesGlobeNewswireSTOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often
- 3mo agoCOLLCollegium Announces $50 Million Accelerated Share Repurchase ProgramGlobeNewswireSTOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often
- 3mo agoCOLLCollegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company ProgressGlobeNewswire– Completed Acquisition of AZSTARYS®, Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM®
- 3mo agoCOLLCollegium to Report Second Quarter 2026 Financial Results on August 6, 2026GlobeNewswireSTOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often
- 3mo agoCOLLCollegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in BostonGlobeNewswireSTOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood
- 4mo agoCOLLApproval of Nucynta Er, Nda #200533 (REMS)FDA Approved DrugsApproval Date: 06/18/2026; Drug Name: Nucynta Er, Nda #200533; Active Ingredients: TAPENTADOL HYDROCHLORIDE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: REMS; Application Number: 200533
- 4mo agoCOLLApproval of Xtampza Er, Nda #208090 (REMS)FDA Approved DrugsApproval Date: 06/18/2026; Drug Name: Xtampza Er, Nda #208090; Active Ingredients: OXYCODONE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: REMS; Application Number: 208090
- 4mo agoCOLLApproval of Nucynta, Nda #022304 (REMS)FDA Approved DrugsApproval Date: 06/18/2026; Drug Name: Nucynta, Nda #022304; Active Ingredients: TAPENTADOL HYDROCHLORIDE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: REMS; Application Number: 022304
- 4mo agoCOLLApproval of Nucynta, Nda #203794 (REMS)FDA Approved DrugsApproval Date: 06/18/2026; Drug Name: Nucynta, Nda #203794; Active Ingredients: TAPENTADOL HYDROCHLORIDE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: REMS; Application Number: 203794
- 5mo agoCOLLCollegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSTOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan (the 2026
- 5mo agoCOLLCollegium to Participate in 2026 Jefferies Global Healthcare ConferenceGlobeNewswireSTOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare
- 6mo agoCOLLCollegium Completes Acquisition of AZSTARYS® from Corium TherapeuticsGlobeNewswire– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Extends Collegium's Long-Term Revenue Outlook; AZSTARYS has Expected Patent Protection
- 6mo agoCOLLCollegium First Quarter 2026 Earnings Conference Call - COLLEGIUM PHARMACEUTICAL INCEarnings Call TranscriptsGreetings, and welcome to the Collegium Pharmaceutical First Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. The question-and-answer session will follow the formal presentat
- 6mo agoCOLLCollegium Reports First Quarter 2026 Financial Results and Highlights Recent Company ProgressGlobeNewswire– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of
- 6mo agoCOLLCollegium to Report First Quarter 2026 Financial Results on May 7, 2026GlobeNewswireSTOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7,
- 7mo agoCOLLCollegium to Participate in Upcoming Investor ConferencesGlobeNewswireSTOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual
- 8mo agoCOLLCollegium to Present New Real-World Data at PainConnect 2026GlobeNewswireSTOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain
- 8mo agoCOLLParis Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD CommunityGlobeNewswire– Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of
- 8mo agoCOLLCollegium to Participate in Upcoming Investor ConferencesGlobeNewswireSTOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global
- 8mo agoCOLLCollegium Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswire– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net
- 8mo agoCOLLBoston Legacy FC Announces Sensory Room Sponsorship with Collegium PharmaceuticalGlobeNewswireBOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Boston Legacy FC today announced a multi-year partnership with Collegium Pharmaceutical, an emerging biopharmaceutical leader in the Boston area, naming the company an Official
- 9mo agoCOLLCollegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026GlobeNewswireSTOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens
- 10mo agoCOLLCollegium to Present Four Real-World Data Posters at APSARD 2026 Annual ConferenceGlobeNewswireSTOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM
- 10mo agoCOLLCollegium Announces the Closing of $980 Million Syndicated Credit FacilityGlobeNewswireSTOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million credit facility
- 10mo agoCOLLApproval of Nucynta, Nda #022304 (Labeling)FDA Approved DrugsApproval Date: 12/22/2025; Drug Name: Nucynta, Nda #022304; Active Ingredients: TAPENTADOL HYDROCHLORIDE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022304
- 10mo agoCOLLApproval of Nucynta Er, Nda #200533 (Labeling)FDA Approved DrugsApproval Date: 12/22/2025; Drug Name: Nucynta Er, Nda #200533; Active Ingredients: TAPENTADOL HYDROCHLORIDE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 200533
- 10mo agoCOLLApproval of Xtampza Er, Nda #208090 (Labeling)FDA Approved DrugsApproval Date: 12/22/2025; Drug Name: Xtampza Er, Nda #208090; Active Ingredients: OXYCODONE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 208090
- 10mo agoCOLLApproval of Nucynta, Nda #203794 (Labeling)FDA Approved DrugsApproval Date: 12/22/2025; Drug Name: Nucynta, Nda #203794; Active Ingredients: TAPENTADOL HYDROCHLORIDE; Company: Collegium Pharm Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 203794
- 12mo agoCOLLCollegium to Participate in Upcoming Investor ConferencesGlobeNewswireSTOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare
- 1y agoCOLLCollegium Reports Third Quarter 2025 Financial Results; Raises 2025 GuidanceGlobeNewswire– Generated Record Quarterly Net Revenue of $209.4 Million, Up 31% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $41.8 Million; Grew Prescriptions by 20% Year-over-Year – – Generated
- 1y agoCOLLKnight Therapeutics Announces Launch of JORNAY PM™ in CanadaGlobeNewswireMONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of JORNAY PM™
- 1y agoCOLLParis Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with TreatmentGlobeNewswire– Long-time advocate, Paris Hilton, shares her personal ADHD journey from childhood to adulthood to encourage others to speak to their healthcare provider about appropriate treatment options – STOUGHTON, Mass.,
- 1y agoCOLLCollegium to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswireSTOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6,
- 1y agoCOLLCollegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute ConferencesGlobeNewswireSTOUGHTON, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will have poster presentations highlighting real-world data from its differentiated neuropsychiatry
- 1y agoCOLLCollegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell RingingGlobeNewswireSTOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management team will ring the Nasdaq opening bell on October 14, 2025 at 9:30 a.m. ET in
- 1y agoCOLLCollegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoCOLLCollegium to Participate in Upcoming Investor ConferencesGlobeNewswireSTOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: 2025 Wells Fargo Healthcare
- 1y agoCOLLCollegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual MeetingGlobeNewswireSTOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at
- 1y agoCOLLCollegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCOLLCollegium Reports Second Quarter 2025 Financial Results; Raises 2025 OutlookGlobeNewswire– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – –
- 1y agoCOLLCollegium to Report Second Quarter 2025 Financial Results on August 7, 2025GlobeNewswireSTOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7,
- 1y agoCOLLCollegium Announces $150 Million Share Repurchase ProgramGlobeNewswireSTOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical
- 1y agoCOLLEBSNTRBNTRBW+2Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030GlobeNewswirePALM BEACH, Fla., June 18, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The market for abuse-deterrent opioids is still developing, but it's estimated that replacing extended-release opioids with
- 1y agoCOLLCollegium to Participate in Upcoming Investor ConferencesGlobeNewswireSTOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro &